Switzerland · Delayed Price · Currency is CHF Xlife Sciences AG Company Description
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector.
The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services.
It also develops novel treatment options in specific indication areas; focuses in the areas of medical technology to develop innovative methods for diagnosing illnesses and/or patient monitoring; and deploys artificial intelligence to improve diagnostic methods and/or processes in the field of biotechnology.
Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.
| Country | Switzerland |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Oliver Baumann |
Contact Details
Address: Talacker 35 Zurich, 8001 Switzerland | |
| Phone | 41 44 385 84 60 |
| Website | xlifesciences.ch |
Stock Details
| Ticker Symbol | XLS |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0461929603 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Oliver R. Baumann | Chief Executive Officer and Executive Director |
| Carl von Halem | Chief Financial Officer |
| Beat Klaui | Head of Accounting and Taxation |
| Dr. Alexander Zink | Chief Scientific Officer |
| Dr. Dennis Fink | Senior Communications and Investor Relations Manager |
| Christian Faber | Head of Legal and Compliance |
| Dr. Frank Ploger | Managing Director of Xlife Sciences USA |